Related Experiment Videos
Modulation of experimental systemic lupus erythematosus with linomide
G Zandman-Goddard1, J George, Y Levy
1Department of Medicine B, Sheba Medical Center, Tel-Hashomer, Israel.
Lupus
|August 1, 1996
Summary
Early administration of linomide, an immunomodulator, reduced autoantibodies in experimental systemic lupus erythematosus (SLE). However, effects diminished after treatment cessation, indicating linomide is effective during early SLE induction.
Area of Science:
- Immunology
- Rheumatology
Background:
- Systemic lupus erythematosus (SLE) is a complex autoimmune disease.
- Early intervention strategies are crucial for managing autoimmune conditions.
Purpose of the Study:
- To evaluate the efficacy of early, low-dose linomide administration.
- To assess linomide's effects in an animal model of experimental SLE.
Main Methods:
- Experimental SLE induced in BALB/c mice via anti-DNA mAb immunization.
- Linomide treatment initiated at pre-disease, early, or late stages.
- Autoantibody levels and clinical parameters (ESR, blood counts, proteinuria) measured via ELISA and other assays.
Main Results:
- Linomide significantly decreased autoantibody levels (50-64%) when given early in experimental SLE.
- No therapeutic effect observed when linomide was administered in later disease stages.
- Preventive effect on SLE induction was noted but lost upon treatment discontinuation.
Conclusions:
- Linomide demonstrates efficacy in the early induction phase of experimental SLE.
- Autoantibody levels rebounded after linomide therapy cessation.
- Early intervention with linomide shows promise but requires sustained administration.